Statin use and cardiovascular risk factors in diabetic patients developing a first myocardial infarction.

Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE

Original Publication: London : BioMed Central, [2002-

Atherosclerosis/*epidemiology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects ; Hypertension/*epidemiology ; Myocardial Infarction/*epidemiology; Adult ; Aged ; Aged, 80 and over ; Atherosclerosis/drug therapy ; Cross-Sectional Studies ; Diabetes Mellitus/drug therapy ; Female ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypertension/drug therapy ; Male ; Middle Aged ; Myocardial Infarction/chemically induced ; Primary Prevention ; Risk Factors

Background: The risk for a first myocardial infarction (MI) in people with diabetes has been shown to be as high as the risk for a new MI in non-diabetic patients with a prior MI. Consequently, risk-reducing statin therapy is recommended for nearly all patients with diabetes 40 years of age or older, regardless of cholesterol level. The purpose of this study was to assess the recommended and real-life use of statins for primary prevention of atherosclerotic cardiovascular disease (ASCVD) in diabetic patients who develop ASCVD.
Methods: In a cross-sectional multicenter study of consecutive patients without previous ASCVD hospitalized with a first MI in 2010-2012, we obtained information on diabetic status, statin use, and cardiovascular risk factors prior to MI.
Results: The study population consisted of 1622 patients with first MI (63 % men), 228 of whom had known diabetes before MI. All but three of the diabetic patients were ≥40 years of age. Diabetic patients were older (70 vs 68, p = 0.006), were more often women (43 vs 36 %, p = 0.05) and had a higher prevalence of statin use (47 vs 11 %, p < 0.001) compared with non-diabetic patients. Despite a high risk factor burden, the majority (53 %) of patients with known diabetes was not treated with statins before MI, and there was no relationship between the number of high-risk markers and statin use. Nearly all diabetic patients not treated with statins before first MI had at least one marker of very high cardiovascular risk, including hypertension (71 %), current smoking (37 %), and nephropathy (33 %).
Conclusions: Primary prevention with statins had been initiated in less than half of diabetic patients destined for a first MI, despite the presence of one or more markers of very high cardiovascular risk in nearly all. These results highlight an urgent need for optimizing statin therapy and global risk factor control in diabetic patients.

J Am Heart Assoc. 2014 Aug;3(4). pii: e001090. doi: 10.1161/JAHA.114.001090. (PMID: 25158866)
Lancet. 2011 Jul 9;378(9786):156-67. (PMID: 21705063)
Lancet. 2010 Jun 26;375(9733):2215-22. (PMID: 20609967)
Cardiovasc Diabetol. 2015;14:122. (PMID: 26382729)
Eur Heart J. 2011 Jul;32(14):1769-818. (PMID: 21712404)
Lancet. 2004 Aug 21-27;364(9435):685-96. (PMID: 15325833)
Eur Heart J. 2013 Oct;34(39):3035-87. (PMID: 23996285)
Cardiovasc Diabetol. 2015;14:14. (PMID: 25645749)
Eur Heart J. 2007 Oct;28(20):2525-38. (PMID: 17951287)
Arch Intern Med. 2010 Jun 28;170(12):1037-44. (PMID: 20585069)
N Engl J Med. 1998 Jul 23;339(4):229-34. (PMID: 9673301)
Eur J Prev Cardiol. 2013 Aug;20(4):658-70. (PMID: 23529608)
Diabet Med. 2014 Dec;31(12):1577-85. (PMID: 25185778)
Cardiovasc Diabetol. 2015;14:24. (PMID: 25885918)
Curr Cardiovasc Risk Rep. 2015;9(7):36. (PMID: 26029318)
Drug Saf. 2016 Jun;39(6):543-59. (PMID: 26979831)
Int J Cardiol. 2013 Jul 31;167(2):342-50. (PMID: 22251416)
Heart. 2014 Apr;100 Suppl 2:ii1-ii67. (PMID: 24667225)
Eur Heart J. 2003 May;24(9):838-44. (PMID: 12727151)
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934. (PMID: 24239923)
Eur Heart J. 2003 Jun;24(11):987-1003. (PMID: 12788299)
Lancet. 2008 Jan 12;371(9607):117-25. (PMID: 18191683)
Eur Heart J. 2003 Sep;24(17):1601-10. (PMID: 12964575)
JAMA. 2001 May 16;285(19):2486-97. (PMID: 11368702)
Eur Heart J. 2012 Jul;33(13):1635-701. (PMID: 22555213)
World J Diabetes. 2012 Dec 15;3(12):186-95. (PMID: 23301120)
Eur Heart J. 2007 Oct;28(19):2375-414. (PMID: 17726041)
Circ Cardiovasc Qual Outcomes. 2012 Nov;5(6):791-7. (PMID: 23132330)
Eur Heart J. 2015 Sep 21;36(36):2446-53. (PMID: 26082084)
Lancet. 2004 Sep 11-17;364(9438):937-52. (PMID: 15364185)
Diabetes Care. 2015 Jan;38 Suppl:S4. (PMID: 25537706)
Prev Med. 2015 Aug;77:131-6. (PMID: 26007299)
Am J Cardiol. 2005 Dec 1;96(11):1469-75. (PMID: 16310424)
Lancet Diabetes Endocrinol. 2015 Jun;3(6):423-30. (PMID: 25935880)
BMJ Open. 2014;4(10):e005991. (PMID: 25326211)
JAMA. 1979 May 11;241(19):2035-8. (PMID: 430798)
Diabet Med. 2011 Mar;28(3):325-32. (PMID: 21309841)
Lancet. 2003 Jun 14;361(9374):2005-16. (PMID: 12814710)
Diabetologia. 2013 Apr;56(4):686-95. (PMID: 23354123)
Prev Med. 2016 Feb;83:63-9. (PMID: 26687101)
JAMA. 2007 Dec 12;298(22):2654-64. (PMID: 18073361)

Keywords: Cardiovascular disease; Diabetes; Myocardial infarction; Prevention; Statin

0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)

Date Created: 20160528 Date Completed: 20170103 Latest Revision: 20181113

20240628

PMC4882784

10.1186/s12933-016-0400-y

27229923